My Watchlist

ALPS Clean Energy ETF

American Strategic Investment Co. Class A Common Stock

CVD Equipment Corporation - Common Stock

Cnb Bk Shs Inc

Columbus Circle Capital Corp II - Class A Ordinary Shares

Columbus Circle Capital Corp II - Unit

Concentra Group Holdings Parent, Inc. Common Stock

Consolidated Edison

Estrella Immunopharma, Inc. - Warrant

FirstEnergy Corp

Fort Technology Inc. - Common Shares

Halozyme Therapeutics, Inc. - Common Stock

Heartland Financial USA, Inc. - Common Stock

Honeywell Aerospace Inc. - Common Stock

Infrastructure Capital Small Cap Income ETF

Intuitive Machines, Inc. - Warrants

Inuvo, Inc.

Jeffs' Brands Ltd - Ordinary Shares

Jeffs' Brands Ltd - Warrant

LAIX Inc. American Depositary Shares, each representing one Class A Ordinary Sh

Legend Biotech Corporation - American Depositary Shares

Lithium Ord Shs

Magnolia Oil & Gas Corporation Class A Common Stock

Morgan Stanley Direct Lending Fund Common Stock

Nanoxplore Inc

PRA Group, Inc. - Common Stock

Restaurant Brands International Inc. Common Shares

Sociedad Quimica y Minera S.A. Common Stock

Spanish Broadcasting System Inc

Stablecoin Development Corporation Common Stock

Switchback Energy Acquisition Corp Cl A

Switchback II Corp Cl A

Edit Watchlist

Top Indices

Dow Jones Industrial Average

NASDAQ Composite

Standard & Poors 500

My Portfolio

Articles published by CuraSen Therapeutics, Inc.

Phase 2a Clinical Data Show CuraSen Therapeutics’ CuraAX (CST-3056) Met Primary Endpoint Demonstrating Statistically Significant Improvement in Standing Systolic Blood Pressure in Patients with Neurogenic Orthostatic Hypotension (nOH)

November 12, 2026

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics to Present Late-Breaking, Phase 2a Exploratory Data with CuraAX (CST-3056) in Patients with Neurogenic Orthostatic Hypotension (nOH) at the 37th International Symposium on the Autonomic Nervous System

November 05, 2026

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium

November 10, 2025

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

October 23, 2025

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial

February 20, 2025

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer

October 15, 2024

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference

March 07, 2024

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease

October 09, 2023

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference

March 30, 2023

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment

December 19, 2022

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease

September 07, 2022

From CuraSen Therapeutics, Inc.

Via Business Wire

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease

November 09, 2021

From CuraSen Therapeutics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.